Gram-Positive Bacterial Infections: all 58 studies

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Optimised Dalbavancin Dosing for Serious Gram-Positive Bacterial InfectionsNot yet recruitingNCT07858526
• Oritavancin for Treatment of Serious Cardiac InfectionsNot yet recruitingNCT07550595Phase 2
• Oritavancin for CIED Infections With MDR Gram-positive CocciNot yet recruitingNCT07013552Not applicable
• Model-informed Precision Dosing for LinezolidNot yet recruitingNCT06444802Phase 3
• Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung DiseaseRecruitingNCT05824988
• Fosfomycin I.v. for Treatment of Severely Infected PatientsRecruitingNCT02979951
• BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)CompletedNCT04044001Phase 1/2Results posted
• TNP-2092 to Treat Acute Bacterial Skin and Skin Structure InfectionCompletedNCT03964493Phase 2Results posted
• Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure InfectionCompletedNCT03747497Phase 2Results posted
• BARDA Securing Anthrax Immunity For the ElderlyCompletedNCT03518125Phase 2Results posted
• ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile InfectionCompletedNCT03183141Phase 3Results posted
• A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)CompletedNCT02750761Phase 1Results posted
• Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)TerminatedNCT02013141Phase 1Results posted
• Post Marketing Surveillance Study on LinezolidCompletedNCT01564758Results posted
• Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their OffspringsCompletedNCT01446289Phase 2Results posted
• Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their OffspringsCompletedNCT01412801Phase 2Results posted
• Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA BacteremiaTerminatedNCT00695903Phase 2Results posted
• Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)TerminatedNCT00638157Phase 4Results posted
• Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure InfectionsCompletedNCT00633152Phase 2Results posted
• A Study of Ceftobiprole in Patients With Fever and Neutropenia.TerminatedNCT00529282Phase 3Results posted
• Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream InfectionsTerminatedNCT00108433Phase 3Results posted
• Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)CompletedNCT00077675Phase 2Results posted
• Telavancin for Treatment of Uncomplicated Staphylococcus Aureus BacteremiaCompletedNCT00062647Phase 2Results posted
• Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)CompletedNCT00061633Phase 2Results posted
• A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant WomenActive, not recruitingNCT06592586Phase 2/3
• ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionTerminatedNCT06418711Phase 3
• The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.Status unknownNCT04917380
• Clinical Decision Support Tool for Vancomycin Dosing in ChildrenCompletedNCT04911270Not applicable
• Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient TransitionTerminatedNCT04847921Phase 2/3
• Dalbavancin Outpatient PilotWithdrawnNCT03982030Phase 4
• PanACEA Sutezolid Dose-finding and Combination EvaluationCompletedNCT03959566Phase 2
• Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)CompletedNCT03896685Phase 3
• Evaluation of the Dosing Regimen of Vancomycin in Pediatric PatientsCompletedNCT03560440
• Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill PatientsStatus unknownNCT03438214Phase 4
• Controlled Human Infection for Vaccination Against Streptococcus PyogenesCompletedNCT03361163Phase 1
• A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World SettingCompletedNCT03159403
• Risk Factors for Staphylococcus Aureus Surgical Site Infections in Orthopedic and Trauma SurgeryStatus unknownNCT03040960
• Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)Approved for marketingNCT02437500
• Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial InfectionsCompletedNCT02134301Phase 1
• Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding StudyStatus unknownNCT01212432Phase 2
• Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile InfectionsWithdrawnNCT01077245Phase 2
• Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic AntibioticsCompletedNCT01019395Phase 1
• Early-Onset Sepsis Surveillance StudyCompletedNCT00874367
• Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and InflammationTerminatedNCT00835783
• What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center?CompletedNCT00736554
• Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive InfectionsCompletedNCT00501150Not applicable
• Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe SepsisCompletedNCT00406198Phase 4
• Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric PatientsTerminatedNCT00240747Phase 3
• Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology UnitsCompletedNCT00167999
• Study Evaluating Vancomycin-Resistant Enterococci in a Hematology UnitCompletedNCT00167960
• Time To Efficacy and Onset Of Action Of LinezolidCompletedNCT00147511Phase 4
• Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard AntibioticsCompletedNCT00136292Phase 1
• Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. AureusCompletedNCT00093067Phase 3
• Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized SubjectsCompletedNCT00081744Phase 3
• Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)CompletedNCT00079976Phase 3
• Daptomycin for the Treatment of Infections Due to Gram-Positive BacteriaTerminatedNCT00055198Phase 3
• Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive BacteriaCompletedNCT00037050Phase 3
• New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)CompletedNCT00035269Phase 3

← Gram-Positive Bacterial Infections overview